Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells
Aneel Paulus(WinnMed), Asher Chanan‐Khan(WinnMed), Stig Linder(Karolinska Institutet), Kasyapa S. Chitta(Mayo Clinic in Florida), Anne J. Novak(Mayo Clinic), Peter Martin(Northwestern University), Davitte Cogen(Mayo Clinic in Florida), Sikander Ailawadhi(Jacksonville College), Sharoon Akhtar(Mayo Clinic in Florida), Stephen M. Ansell(Mayo Clinic), Shumail M. Paulus(Jacksonville College), Brandy Edenfield(Mayo Clinic in Florida), Yamima Bashir(Mayo Clinic in Florida), Thomas R. Caulfield(Jacksonville College), Jennifer Jiang(European Society for Blood and Marrow Transplantation), Hamza Yousaf(Mayo Clinic in Florida), Kelara Samuel(Mayo Clinic in Florida), Morton Coleman(Cornell University), Vivek Roy(Jacksonville College), Thomas E. Witzig(WinnMed), Roman Hudec(Mayo Clinic in Florida), Diem Hong Tran(Children's Medical Center)
Cited by 63
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k